Recent Updates
Recently added Catalysts
ONC Positive Sentiment

Samenvatting: BeOne Medicines en Revolution Medicines kondigen samenwerking aan voor klinische ontwikkeling en regionale commercialisering

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines and Revolution Medicines have announced a multi-faceted collaboration aimed at advancing clinical development and regional commercialization of targeted therapies for RAS-dependent cancers. This partnership combines the strengths of both companies to enhance their capabilities in oncology. The collaboration is expected to accelerate the development of innovative treatment options.
Price reaction · baseline $358.66 (2026-08-10T17:02:00.000Z) · hit during market hours · clean, no other ONC news in the window
day 0 close · peak
+0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration aims to enhance clinical development.
  • Focus on targeted therapies for RAS-dependent cancers.
  • Partnership between two innovative oncology companies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
lenvatinib
Phase 2 · Advanced Solid Tumor

Full Press Release Details

SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een wereldwijd oncologiebedrijf, en Revolution Medicines, Inc. (Nasdaq: RVMD), een oncologiebedrijf dat zich in een vergevorderd stadium van klinisch onderzoek bevindt en doelgerichte therapieën ontwikkelt voor patiënten met RAS-afhankelijke kankersoorten, hebben vandaag een meerledige samenwerking aangekondigd. Deze omvat een klinisch samenwerkingsverband om combinaties te

Frequently Asked Questions

What companies are collaborating?

BeOne Medicines and Revolution Medicines are collaborating.

What is the focus of the collaboration?

The collaboration focuses on clinical development for RAS-dependent cancers.

What type of therapies are being developed?

Targeted therapies for patients with RAS-dependent cancers are being developed.

Where are BeOne and Revolution based?

BeOne is based in San Carlos, and Revolution is in Redwood City, California.

ShareAdd on Google
Tags: ONC Viatris Investor Conferences Healthcare BeOne Medicines Revolution Medicines oncology RAS-dependent cancers clinical development
Last updated: Aug 10, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
lenvatinibPhase 2
Advanced Solid Tumor →

Catalyst track record

+15%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →